Bacitracin, neomycin, polymyxin topical

Bacitracin Polymyxin B, Topical (Polysporin) Bacitracin, Neomycin, Polymyxin B, Topical (Neosporin Ointment) Bacitracin, Neomycin, Pol5rm5 xm B, Hydrocortisone, Topical (Cortisporin)... 

Bacitracin, Neomycin, Polymyxin B, Lidocaine, Topical (Clomycin)... 

In conclusion, evidence exists for the topical use of mupirocin, polysporin B, and to a lesser degree PVI for CLABSI prevention. The potential for mupirocin resistance development has to be considered. Currently, while gramicidin is not available in the US, a similar preparation in the form of bacitracin/neomycin/ polymyxin B is commonly used. 

Gramicidin is available only for topical use, in combination with other antibiotics such as neomycin, polymyxin, bacitracin, and nystatin. Systemic toxicity limits this drug to topical use. The incidence of sensitization following topical application is exceedingly low in therapeutic concentrations. 

The closely related neomycin, obtained from S. fradiae, as a mixture of epimers NM B and C (Fig. 6-22), also exhibited a broad antibacterial spectrum. However, high nephrotoxicity precludes systemic use. Oral administration for gut sterilization preceding bowel surgery is actually a local application, as is, of course, the use of NM in a number of topical creams and lotions, usually in combination with bacitracin and polymyxin. 

Systemic therapy with a variety of (3-lactams, macro-lides and lincosamides (clindamycin) has been the cornerstone of skin infection therapy for many years [17]. However, topical antibiotics can play an important role in both treatment and prevention of many primary cutaneous bacterial infections commonly seen in the dermatological practice [18], Indeed, while systemic antimicrobials are needed in the complicated infections of skin and skin structure, the milder forms can be successfully treated with topical therapy alone [18], The topical agents used most often in the treatment of superficial cutaneous bacterial infections are tetracyclines, mupirocin, bacitracin, polymyxin B, and neomycin. 

Bacitracin is highly nephrotoxic when administered systemically and is only used topically (Chapter 62). Bacitracin is poorly absorbed. Topical application results in local antibacterial activity without systemic toxicity. Bacitracin, 500 units/g in an ointment base (often combined with polymyxin or neomycin), is indicated for the suppression of mixed bacterial flora in surface lesions of the skin, in wounds, or on mucous membranes. Solutions of bacitracin containing 100-200 units/mL in saline can be used for irrigation of joints, wounds, or the pleural cavity. 

---